Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

David Andorsky, Sarah Tomassetti, Yehuda E. Deutsch, E Randolph Broun, Ghayas C. Issa, Moshe Y. Levy, Michael W. Deininger, Rodrigo Maegawa, Alok Shrestha, Michael J. Mauro

Blood (2021) 138 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2021-147337

Published: 2021

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Yumeng Zhang, MD, Hannah H Asghari, MD, Onyee Chan, MD, Dasom Lee, MD, Martine Extermann, MD, Najla Al Ali, M.Sc, Yehuda E. Deutsch, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, David A Sallman, MD, Chetasi Talati, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 1368.

https://doi.org/10.1182/blood-2019-127772

Published: 2019

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Yehuda E. Deutsch, MD, Justin T Presutto, PharmD, MBA, Amanda Brahim, Pharm.D., Jyotishankar Raychaudhuri, MD, Marco Andres Ruiz, MD, Jose Sandoval-Sus, MD, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2018-99-115682

Published: 2018

Journal Articles

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Todd C. Knepper, PharmD, Yehuda E. Deutsch, MD, Chirag K Bhagat, PharmD, Justin M Watts, MD, Terrence J Bradley, MD, Wassim Samra, MD, Mohammad Omar Hussaini, MD, Kendra L. Sweet, MD, Chetasi Talati, MD, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A Sallman, MD

Blood (2018) 132 (Supplement 1): 1524.

https://doi.org/10.1182/blood-2018-99-113088

Published: 2018

Journal Articles

Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML

Yehuda E. Deutsch, MD, Aymee Perez, PhD, Ana Rodrigues, BS, Ezra S. Blumenthal, Elena Cubedo, PhD, Justin M. Watts, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Arthur Zelent, PhD

Blood (2014) 124 (21): 2300.

https://doi.org/10.1182/blood.V124.21.2300.2300

Published: 2014

Journal Articles

Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?

Yehuda E. Deutsch, MD, German Campuzano-Zuluaga, MD, Matthew P Salzberg, Alexandra Gomez Arteaga, MD, Justin M. Watts, MD, Jennifer R Chapman, MD, Offiong F Ikpatt, MD, Francisco Vega, MD PhD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2014) 124 (21): 1004.

https://doi.org/10.1182/blood.V124.21.1004.1004

Published: 2014

Journal Articles

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Yehuda E. Deutsch, MD, Daniel J Dammrich, MD, Jesus C Fabregas, MD, Agustin Pimentel, MD, Alexandra Stefanovic, MD, James E. Hoffman, MD

Blood (2013) 122 (21): 5399.

https://doi.org/10.1182/blood.V122.21.5399.5399

Published: 2013

Journal Articles

Identification of a defective factor XI cross-reacting material in a factor XI-deficient patient

C Mannhalter, P Hellstern, E Deutsch

Blood (1987) 70 (1): 31–37.

https://doi.org/10.1182/blood.V70.1.31.31

Published: 1987

NARROW

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Sodium Salicylate Has a Priming Effect When Combined with Azacitidine in Pre-Clinical Models of AML

Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Identification of a defective factor XI cross-reacting material in a factor XI-deficient patient

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only